Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05463731 · ClinicalTrials.gov registry record · Phase 3
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
A Phase 3 study of Alzheimers Disease, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 3
- Development phase
- 1,667
- Enrollment target
- 20
- Study locations
NCT05463731: Active Phase 3 study of Alzheimers Disease, sponsored by Eli Lilly and Company.
NCT05463731 is a Phase 3 study of Alzheimers Disease that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 1,667 participants, below the 3,915-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (57% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05463731, a Phase 3 study of Alzheimers Disease, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,667 participants
- Enrollment target
- 20
- Study locations
Study Summary
The reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early symptomatic Alzheimer's disease (AD).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Remternetug (SC)
- DRUG Remternetug (IV)
Study Locations (20)
California
- Hope Clinical Research, Inc. - Canoga Park
- North County Neurology Associates - Carlsbad
- Wr- Pri, Llc - Encino
- Neuro-Pain Medical Center - Fresno
- Irvine Clinical Research - Irvine
- Kaizen Brain Center - La Jolla
- Anderson Clinical Research - Redlands
Florida
- JEM Research Institute - Atlantis
- VIN-Julie Schwartzbard - Aventura
- Brain Matters Research - Delray Beach
- Neuropsychiatric Research Center of Southwest Florida - Fort Myers
- Finlay Medical Research - Greenacres City
- Encore Research Group- Jacksonville Center for Clinical Research - Jacksonville
- ClinCloud - Maitland - Maitland
Colorado
- Mountain Neurological Research Center - Basalt
- Alpine Clinical Research Center - Boulder
- Colorado Springs Neurological Associates - Colorado Springs
Connecticut
- Institute for Neurodegenerative Disorders - New Haven
- Ki Health Partners, LLc, dba New England Institute for Clinical Research - Stamford
Arizona
- MD First Research - Chandler - Chandler
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,667 participants |
| Start Date | 2022-08-01 |
| Est. Completion | 2026-03 |
| Phase | Phase 3 |
What the registry record for NCT05463731 still lists
NCT05463731 is an interventional study that assigns participants to a tested intervention. Its 1,667 participants enrollment target places it among the larger protocols in the corpus, below the 3,915-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (57% lower).
The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05463731 names 20 study sites across 5 states, led by California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT05463731 about?
NCT05463731 is a clinical study titled "A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)". The reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early symptomatic Alzheimer's disease (AD).
What is the current status of trial NCT05463731?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,667 participants. The study started on 2022-08-01. Estimated completion is 2026-03.
What conditions does trial NCT05463731 study?
This clinical trial studies the following conditions: Alzheimers Disease.
What interventions are being tested in trial NCT05463731?
The interventions under investigation include: Placebo (DRUG), Remternetug (SC) (DRUG), Remternetug (IV) (DRUG).
Who is sponsoring clinical trial NCT05463731?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05463731 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05463731's enrollment target sits among peer trials
1,667 9th of 147 higher than 139 of 147 other Alzheimers Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimers Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
RECRUITING · Phase 3
-
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
RECRUITING · Phase 3
-
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
RECRUITING · Phase 3
-
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06644625 · 1,665 participants
CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study
- NCT04852887 · 1,670 participants · Phase 3
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
- NCT06034405 · 1,663 participants
Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis
- NCT06401330 · 1,656 participants · Phase 3
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI